Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Refractory Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00888472
Recruitment Status : Completed
First Posted : April 27, 2009
Last Update Posted : February 5, 2013
Information provided by (Responsible Party):
Tamotsu Ishizuka, Gunma University

Brief Summary:
Extracorporeal leukocytapheresis (LCAP) or granulocytapheresis (GCAP) has been used in the treatment of patients with rheumatoid arthritis and ulcerative colitis and has shown promising safety and efficacy. LCAP and GCAP seem to be effective for steroid-resistant inflammation. The investigators have already reported safety and efficacy of GCAP in refractory asthma and expect the beneficial effect of LCAP in refractory asthma. In this study, in order to improve the therapeutic effect of LCAP by increasing the quantity of leukocytes that were removed, the investigators conducted a clinical study to investigate safety and efficacy of high-dose LCAP performed using a larger filter and an increased dose of the blood volume per body weight treated, as an possible therapy for refractory asthma.

Condition or disease Intervention/treatment Phase
Bronchial Asthma Procedure: Leukocytapheresis Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Patients With Refractory Asthma
Study Start Date : November 2008
Actual Primary Completion Date : November 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: 1 Procedure: Leukocytapheresis
5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.

Primary Outcome Measures :
  1. Improvement of morning peak flow rate (PEFR) or evening PEFR [ Time Frame: 4 weeks after the treatment ]

Secondary Outcome Measures :
  1. An improved score of asthma control test [ Time Frame: 4 weeks after the treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients fulfilled the 2001 criteria for refractory asthma in American Thoracic Society.

Exclusion Criteria:

  • Pregnant women.
  • Patients with severe cardiovascular diseases.
  • Patients with infective diseases.
  • Patients with leukocytopenia or anemia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00888472

Department Medicine and Molecular Science, Gunma University Graduate School of Medicine
Maebashi, Gunma, Japan, 371-8511
Sponsors and Collaborators
Gunma University
Principal Investigator: Tamotsu Ishizuka, M.D. Assistant Professor

Responsible Party: Tamotsu Ishizuka, Clinical Professor, Gunma University Identifier: NCT00888472     History of Changes
First Posted: April 27, 2009    Key Record Dates
Last Update Posted: February 5, 2013
Last Verified: February 2013

Keywords provided by Tamotsu Ishizuka, Gunma University:
Extracorporeal leukocytapheresis

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases